DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Hemophilia A and B Recombinant Factor Replacement Therapy - US Drug Forecast and Market Analysis to 2024" report to their offering.
The US is the largest global hemophilia market, due to high rates of disease diagnosis combined with high rates of primary rFVIII and rFIX prophylaxis among diagnosed severe hemophilia A and B patients. This market growth will be driven by increasing rates of prevalent cases of hemophilia A and B, and increasing uses of recombinant replacement factors in hemophilia A and B patients over the forecast period.
- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Hemophilia A and B market.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
5.2 Strategic Competitive Assessment
5.3 Product Profiles - Hemophilia A
5.4 Product Profiles - Hemophilia B
5.5 Product Profiles - Hemophilia A and B with Inhibitors
6 Unmet Need and Opportunity
6.2 Opportunity Analysis
6.3 Unmet Needs Gap Analysis
7 Pipeline Assessment
7.2 Late-Stage Development Candidates - Hemophilia A
7.3 Late-Stage Development Candidates - Hemophilia B
7.4 Late-Stage Development Candidates - Hemophilia A and B Bypassing Agents (Patients with Inhibitors)
7.5 Promising Drugs in Early-Stage Development
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/f5txhf/hemophilia_a_and